John Cowden, MD
Pulmonary Disease · Longmont, CONPI 1982665071
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 82.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $2,388, more than ten times the $156 reported in 2019.
Across 70 payments — averaging $96.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Pulmonx Corporation$249
- Boehringer Ingelheim$236
- United Therapeutics Corporation$156
- Bayer$139
- Merck$112
- plus $281 from 8 others
Across 3 payments — averaging $18,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$55K
What the payments were for
- Speaking & faculty fees$5007%
- Travel & lodging$3,72755%
- Food & beverage$2,22733%
- Education$2674%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 39 | $5,547 |
| Pulmonx Corporation | 3 | $249 |
| Boehringer Ingelheim | 3 | $236 |
| United Therapeutics Corporation | 7 | $156 |
| Bayer | 2 | $139 |
| Merck | 3 | $112 |
| Boston Scientific | 1 | $70 |
| Mylan Specialty L.p. | 3 | $64 |
| Novartis | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Gilead | 2 | $26 |
| Grifols USA, LLC | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,721 in reported general payments places this provider in the 75th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $381,889 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $103,431 |
| Spiriva RespimatTiotropium Bromide | 91 | $52,344 |
| Spiriva HandihalerTiotropium Bromide | 28 | $24,771 |
| EliquisApixaban | 20 | $17,226 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $16,619 |
| Sildenafil Citrate | 36 | $11,995 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,356 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,572 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,110 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $6,564 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,234 |
| Mycophenolate Mofetil | 54 | $4,924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $4,131 |
| PlavixClopidogrel Bisulfate | 13 | $3,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $236 | $442,805134 claims |
| AstraZenecaSymbicort | $16 | $9,35627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Longmont
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.